Dr. Steven M. Duffy
Claim this profileHematology Oncology Associates of Central New York-East Syracuse
Area of expertise
Breast Cancer
Steven M. Duffy has run 6 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Steven M. Duffy has run 5 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Hematology Oncology Associates Of Central New York-East Syracuse
Hematology Oncology Associates Of Central New York-Onondaga Hill
Clinical Trials Steven M. Duffy is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting
2 awards
Phase 3
32 criteria
Zanubrutinib
for Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting
2 awards
Phase 3
10 criteria
More about Steven M. Duffy
Clinical Trial Related
5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 10 Active Clinical Trials
Treatments Steven M. Duffy has experience with
- Biospecimen Collection
- Pembrolizumab
- Carboplatin
- Tamoxifen
- Atezolizumab
- Durvalumab
Breakdown of trials Steven M. Duffy has run
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven M. Duffy specialize in?
Steven M. Duffy focuses on Breast Cancer and Lung Cancer. In particular, much of their work with Breast Cancer has involved ER positive patients, or patients who are HER2 positive.
Is Steven M. Duffy currently recruiting for clinical trials?
Yes, Steven M. Duffy is currently recruiting for 10 clinical trials in East Syracuse New York. If you're interested in participating, you should apply.
Are there any treatments that Steven M. Duffy has studied deeply?
Yes, Steven M. Duffy has studied treatments such as Biospecimen Collection, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Steven M. Duffy?
Apply for one of the trials that Steven M. Duffy is conducting.
What is the office address of Steven M. Duffy?
The office of Steven M. Duffy is located at: Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York 13057 United States. This is the address for their practice at the Hematology Oncology Associates of Central New York-East Syracuse.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.